Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis: Post-hoc analysis of a multicentre, prospective, real-world study

Wenting Sun, Keqin Hua, Li Hong, Juxin Zhang, Min Hao, Jianliu Wang, Jun Zhang, Valerie Perrot, Hongbo Li, Xinmei Zhang, Wenting Sun, Keqin Hua, Li Hong, Juxin Zhang, Min Hao, Jianliu Wang, Jun Zhang, Valerie Perrot, Hongbo Li, Xinmei Zhang

Abstract

Triptorelin has been used after surgery in deep infiltrating endometriosis. This post-hoc analysis aimed to evaluate symptom control between patients receiving 1-3 triptorelin injections and those receiving 4-6 injections within 24 months of conservative surgery for deep infiltrating endometriosis, in the real-world.Included patients were divided into two groups (received up to 3 months injections in group A, 4-6 injections in group B) based on the numbers of triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) administration. Evolution in score of pain intensity at 3, 6, 9, 12, 18, and 24 months after primary triptorelin administration and symptom improvement/recurrence rates between two groups were compared. Symptoms of pain intensity were assessed using a visual analogue scale (VAS) with a range from 0 to 10 cm. An improvement in symptoms was defined as a reduction of at least 3 cm or 3 units from pre-surgery levels.156 patients in group A and 228 in group B. Pain symptom score (mean ± standard deviation) diminished to a nadir at 3-months for group A and 6-months for group B; at 6-months nadir scores were significantly lower in group B (0.9 ± 1.7 vs 0.4 ± 1.2 respectively, P = .002). No significant difference for pain symptom scores between both groups at 24-months (P = .269). The 6-month and 24-month cumulative improvement rates of pain (80.6% vs 89.8%, P = .014 and 82.6% vs 90.7%, P = .025) and gastro-intestinal symptoms (61.0% vs 80.8%, P = .022 and 61.0% vs 83.3%, P = .008) were significantly higher in group B, whereas there was no significant difference in rates of menstrual disorders and urinary symptoms. There is no significant difference for 12-months and 24-months cumulative recurrence rates of total symptoms between both groups (11.3% vs 13.8%, P = .568 and 16.1% vs 26.0%, P = .094).In women with deep infiltrating endometriosis, longer treatment with triptorelin following conservative surgery was associated with a decrease in symptom intensity and greater improvement of pain symptoms in the short-term and greater improvement of gastro-intestinal symptoms in the long-term.Trial registration number: ClinicalTrials.gov, NCT01942369.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Flow diagram of study population.
Figure 2
Figure 2
Proportion of patients with different symptom intensity pre-surgery.
Figure 3
Figure 3
Summary of symptoms scores for study population in 24 months.

References

    1. Chapron C, Jacob S, Dubuisson JB, Vieira M, Liaras E, Fauconnier A. Laparoscopically assisted vaginal management of deep endometriosis infiltrating the rectovaginal septum. Acta Obstet Gynecol Scand 2001;80:349–54.
    1. Angioni S, Pontis A, Dessole M, Surico D, De Cicco Nardone C, Melis I. Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery. Arch Gynecol Obstet 2015;291:363–70.
    1. Cohen J, Ballester M, Selleret L, et al. . Finding the balance between surgery and medically-assisted reproduction in women with deep infiltrating endometriosis. Minerva Ginecol 2016;68:642–52.
    1. Koninckx PR, Ussia A, Adamyan L, Wattiez A, Donnez J. Deep endometriosis: definition, diagnosis, and treatment. Fertil Steril 2012;98:564–71.
    1. Szubert M, Zietara M, Suzin J. Conservative treatment of deep infiltrating endometriosis: review of existing options. Gynecol Endocrinol 2018;34:10–4.
    1. Araujo SE, Seid VE, Marques RM, Gomes MT. Advantages of the robotic approach to deep infiltrating rectal endometriosis: because less is more. J Robot Surg 2016;10:165–9.
    1. Wilczynski M, Wiecka-Plusa M, Antosiak B, Maciolek-Blewniewska G, Majchrzak-Baczmanska D, Malinowski A. Rectovaginal endometriosis--analysis of 160 cases. Ginekol Pol 2015;86:896–901.
    1. Hudelist G, Aas-Eng MK, Birsan T, et al. . Pain and fertility outcomes of nerve-sparing, full-thickness disk or segmental bowel resection for deep infiltrating endometriosis-A prospective cohort study. Acta Obstet Gynecol Scand 2018;97:1438–46.
    1. Uccella S, Gisone B, Serati M, et al. . Functional outcomes of nerve-sparing laparoscopic eradication of deep infiltrating endometriosis: a prospective analysis using validated questionnaires. Arch Gynecol Obstet 2018;298:639–47.
    1. Derouich S, Attia L, Slimani O, et al. . Medical treatment of endometriosis. Tunis Med 2015;93:407–12.
    1. Slopien R, Meczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny 2016;15:43–7.
    1. Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol 2018;51:68–91.
    1. Leone Roberti Maggiore U, Scala C, Remorgida V, et al. . Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother 2014;15:1153–79.
    1. Xue H, Liu M, Hao W, Li Y. Clinical evaluation of laparoscopic surgery combined with triptorelin acetate in patients with endometriosis and infertility. Pak J Med Sci 2018;34:1064–9.
    1. Zhong YJ, Zhang W, Zhang WT, Cheng J, Lu QY, Zeng KK. Efficacy and safety of GnRH-a combine with laparoscope conservative surgery in the treatment of the moderate or severe endometriosis. Zhonghua Fu Chan Ke Za Zhi 2013;48:180–2.
    1. Li Z, Zhang HY, Zhu YJ, Hu YJ, Qu PP. A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women. Eur J Obstet Gynecol Reprod Biol 2014;183:164–8.
    1. Choktanasiri W, Boonkasemsanti W, Sittisomwong T, et al. . Long-acting triptorelin for the treatment of endometriosis. Int J Gynaecol Obstet 1996;54:237–43.
    1. Bergqvist A, Bergh T, Hogstrom L, Mattsson S, Nordenskjold F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril 1998;69:702–8.
    1. Kang JL, Wang XX, Nie ML, Huang XH. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest 2010;69:73–7.
    1. Liu DY, Gu MF, Shu JZ, Shi YX, Wang CY, Han ZQ. Efect of triptorelin and an extended-interval dosing regim en in the treatment of patients with endometriosis and adenomyoma. Chin J Obstet Gynecol 2006;41:656–9.
    1. Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 2008;136:194–8.
    1. Parazzini F, Viganò P, Candiani M, Fedele L. Diet and endometriosis risk: a literature review. Reproductive BioMedicine Online 2013;26:323–36.
    1. Harris HR, Chavarro JE, Malspeis S, et al. . Dairy-food, calcium, magnesium, and vitamin D intake and endometriosis. Am J Epidemiol 2013;177:420–30.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅